GlassScriptPhysician profile
Dewan E Smith-Williams
NPI 1851831556
$13,864.93
in general payments reported to CMS, 2019-2025
28 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,333 · 2022: $1,448 · 2023: $3,594 · 2024: $5,239 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,897 · Consulting Fee: $115 · Education: $71.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,897.20 |
| Consulting Fee | $115.00 |
| Education | $71.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,729.21 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,586.87 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,509.94 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,249.99 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $1,187.18 | 2021-2024 | Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $973.15 | 2022-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $663.71 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $624.93 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Indivior INC. | $603.24 | 2021-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $580.75 | 2021-2024 | Spravato, Invega Sustenna, Invega |
| Neurocrine Biosciences, INC. | $556.63 | 2021-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $437.05 | 2021-2024 | Fanapt, Hetlioz |
| Corium, LLC | $381.69 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $267.23 | 2024 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $235.84 | 2023-2024 | Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $231.77 | 2023-2024 | Loreev Xr |
| Eisai INC. | $153.63 | 2021 | |
| Sunovion Pharmaceuticals INC. | $145.26 | 2021 | |
| Validus Pharmaceuticals LLC | $142.85 | 2021-2024 | Equetro |
| Takeda Pharmaceuticals U.S.A., INC. | $126.23 | 2022-2024 | Trintellix |
| Braeburn INC. | $115.32 | 2023-2025 | Brixadi |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Noven Therapeutics, LLC | $106.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $52.23 | 2022 | |
| Neuronetics, INC. | $35.32 | 2023 | Neurostar Tms Therapy System |
| Orexo US, INC. | $24.29 | 2024 | Zubsolv |
| Tempus Ai, INC | $15.23 | 2024 | |
| Tris Pharma INC | $13.52 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dewan Smith-Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.